ETF Components for XBI - SPDR S&P Biotech ETF


Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

Holdings

Symbol Grade Price % Change Allocation
NTRA A 0.77 3.30
INCY C -0.66 3.29
GILD B 0.71 2.90
UTHR C 1.10 2.88
NBIX C 1.36 2.62
VRTX D -1.00 2.62
INSM C -0.19 2.43
ALNY D 0.43 2.38
ABBV F 1.88 2.33
AMGN D 0.26 2.28
SRPT F -0.76 2.28
BIIB F 1.21 2.19
MDGL C 1.32 2.17
EXAS D 1.33 2.05
VKTX F 2.58 2.00
BMRN F 0.11 1.98
REGN F 0.22 1.80
CYTK D -1.36 1.79
BPMC C 1.37 1.69
CRSP D -2.52 1.63
TGTX B 12.63 1.62
MRNA F -0.16 1.57
RVMD B 1.68 1.46
RNA C 0.17 1.32
KRYS C 0.02 1.29
HALO F -0.93 1.27
EXEL B 0.40 1.23
ADMA B 0.69 1.23
ROIV D 3.57 1.18
ALKS C -0.43 1.13
IONS F -1.07 1.08
TWST F 1.62 0.93
PCVX D 1.93 0.90
IOVA F 2.21 0.88
BBIO F 2.00 0.87
APLS F -0.44 0.86
GERN C 0.63 0.86
CRNX B 1.82 0.84
ACLX C 1.81 0.79
DYN D 0.60 0.78
ACAD C -1.17 0.78
SWTX C -1.63 0.77
AGIO C 1.03 0.76
BEAM D -2.25 0.72
RARE F 0.85 0.69
RXRX D -5.71 0.66
PTCT B 1.20 0.64
FOLD F -0.52 0.63
IMVT F 1.41 0.62
RYTM C 0.88 0.61
NUVL D 2.37 0.60
NTLA F 8.08 0.58
PTGX D 4.06 0.58
VERA C 4.37 0.57
MIRM B -1.46 0.57
ARWR D -1.12 0.54
IDYA F 1.25 0.53
VCYT B 1.02 0.53
JANX C -2.08 0.51
SRRK B -7.04 0.49
DVAX C 1.11 0.49
NVAX F 1.30 0.47
ARDX F 3.05 0.47
VCEL A -0.42 0.46
DNLI D -1.92 0.46
KYMR D -1.09 0.45
SNDX F -1.07 0.44
AKRO C -0.21 0.43
CGON F 0.59 0.42
ARQT B 1.87 0.42
BCRX D 1.03 0.42
CPRX C -0.66 0.41
KROS D -0.54 0.36
IRON B 2.23 0.34
MNKD B -0.51 0.34
CLDX D 2.35 0.34
NRIX C 1.10 0.33
SMMT D -0.59 0.33
VRDN D 1.21 0.30
RCKT F -0.23 0.28
DAWN D -0.65 0.28
MYGN F 0.20 0.27
IRWD F -2.84 0.26
TVTX C 3.02 0.26
CGEM F -3.10 0.25
CDNA D -0.22 0.24
KURA F -37.27 0.24
XNCR B 0.82 0.24
APLT B -0.69 0.22
CDMO A 0.57 0.22
RCUS F -1.16 0.20
VIR F -1.41 0.20
EBS C 7.43 0.20
REPL C -1.16 0.18
HUMA F 4.20 0.18
ALT C 8.37 0.18
SPRY C 0.44 0.18
AVXL B 6.19 0.17
ARCT F 1.79 0.17
ANNX F 3.88 0.16
STOK D 1.95 0.16
ETNB D 1.50 0.16
MDXG B 2.65 0.16
COGT D 1.65 0.16
VERV D 1.32 0.15
RLAY F 0.11 0.14
OLMA F -1.45 0.13
IMNM F 2.09 0.13
PRTA F 0.41 0.13
OCGN F -0.49 0.12
ANAB F 3.99 0.12
FDMT F -2.73 0.12
SANA F -4.55 0.12
RGNX D -2.60 0.12
ALLO F 2.93 0.11
CELC F 0.08 0.11
SAGE F 2.24 0.11
CCCC F 0.74 0.10
ERAS C -3.22 0.10
ORIC F -0.46 0.09
FATE F -6.53 0.08
SVRA F 5.43 0.08
ABUS D 1.60 0.07
KALV F 2.23 0.07
SCLX F -0.85 0.06
YMAB F -0.14 0.06
ITOS F 3.31 0.06
ALEC F 2.06 0.04

Recent News for SPDR S&P Biotech ETF & its Holdings

Date Stock Title
Nov 21 MRNA Major companies that are also popular short-selling stocks
Nov 21 KURA Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
Nov 21 HUMA Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
Nov 21 KURA Kura Oncology partners Kyowa Kirin to advance AML treatment
Nov 21 AMGN Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares
Nov 21 TGTX TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Nov 21 AMGN Amgen picks prolific biotech founder Chang as new top scientist
Nov 21 AMGN Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 21 CRSP CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
Nov 20 KURA Kura stock slides 17% on Kyowa Kirin deal for ziftomenib
Nov 20 KURA Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 20 MYGN Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Nov 20 NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Nov 20 AMGN AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
Nov 20 MRNA CDC warns of an imminent spike in COVID, flu cases
Nov 20 INSM Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
Nov 20 MDGL Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra
Nov 20 SWTX SpringWorks started at outperform by Evercore ahead of FDA decision
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a replication strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Index Fund Stock Market Index Biotechnology S&P Total Market Index ( Biotechnology Segment
Back to the Main XBI Page...